Skip to main content
Caplight Logo









Inteliphage

Inteliphage

Private
BelgiumHealthcare & Life Scienceshttps://www.inteliphage.com/

Last Round

Grant

Jan 17, 2023

Total Funding Raised

$16.74M

Company Overview

Inteliphage is a biotechnology company developing evidence-driven, personalized phage-based therapies for patients with difficult-to-treat infections.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Hardware + Subscription, Government Contracts

AI Layer

Non-AI

Keywords

phage therapybacteriophage therapypersonalized phage therapyantimicrobial resistanceAMRphage diagnosticsphage librarymulti-drug resistant infectionssuperbug treatmentphage susceptibility testingphagogramphage bankingGMP phage supplyESKAPE pathogensprecision medicinebiologics manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inteliphage Comparables

Compare Inteliphage with similar companies based on industry and business-model similarity.

Inteliphage comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fagoterapia LAB
80%
PhageOne
80%
Eliava BioPreparations
79%

Inteliphage Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 17, 2023
Series AJun 1, 2021

Inteliphage Investors

Notable investors and investment history

Inteliphage investors
InvestorRounds
European Innovation Council FundGrant
BioWinGrant
Walloon Region (Belgium)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 17, 2023

    Secured $1.94M from the European Innovation Council.

  • Jun 1, 2021

    $4M round raised

Inteliphage Filings

Explore SEC and related filing metadata, where available.

Inteliphage filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Inteliphage's valuation, stock price, and market status.

Is Inteliphage a public or private company?

Inteliphage is a private company.

What is the current stock price of Inteliphage?

Inteliphage is a private company with no public stock price. No recent secondary market data is available.

How much is Inteliphage worth (valuation)?

Valuation information for Inteliphage is not publicly available.

Can I buy Inteliphage stock?

Inteliphage shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Inteliphage's last funding round?

Inteliphage's most recent funding round was Grant on January 17, 2023.

Who are the main investors in Inteliphage?

Key investors in Inteliphage include European Innovation Council, BioWin, Walloon Region (Belgium).

Will Inteliphage IPO soon?

No public IPO plans have been announced for Inteliphage.

How can I track Inteliphage secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Inteliphage's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBelgium
Year Founded2018
Last FundingJan 17, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?